MorphoSys AG updated Monjuvi U.S. net product sales guidance for the year 2022. Monjuvi U.S. Net Product Sales expects to be USD 90 million to USD 110 million compared to USD 110 million to USD 135 million previous guidance.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.65 EUR | +0.83% | -1.77% | +96.03% |
04-30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
04-30 | MorphoSys AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.03% | 2.7B | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- MOR Stock
- News MorphoSys AG
- Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022